

Case report

Open Access

Simultaneous sleep study and nasoendoscopic investigation in a patient with obstructive sleep apnoea syndrome refractory to continuous positive airway pressure: a case report

Claudia Chaves Loureiro*¹, Marta Drummond², Adriana Magalhães², Elisabete SantaClara², Miguel Gonçalves² and João Carlos Winck²

Addresses: ¹Department of Pulmonology, University Hospital of Coimbra, Coimbra, Portugal and ²Department of Pulmonology, São João do Porto Hospital, Porto, Portugal

E-mail: Claudia Chaves Loureiro* - cl_loureiro@hotmail.com; Marta Drummond - marta.drummond@gmail.com; Adriana Magalhães - pneumologia@hsjoao.min-saude.pt; Elisabete SantaClara - pneumologia@hsjoao.min-saude.pt; Miguel Gonçalves - pneumologia@hsjoao.min-saude.pt; João Carlos Winck - jwinck@hsjoao.min-saude.pt

*Corresponding author

Published: 2 December 2009

Received: 12 November 2009

Journal of Medical Case Reports 2009, **3**:9315 doi: 10.1186/1752-1947-3-9315

Accepted: 2 December 2009

This article is available from: <http://www.jmedicalcasereports.com/content/3/1/9315>

© 2009 Loureiro et al; licensee BioMed Central Ltd.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/2.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Introduction: The standard treatment for obstructive sleep apnoea syndrome is nasal continuous positive airway pressure. In most cases the obstruction is located at the oropharyngeal level, and nasal continuous positive airway pressure is usually effective. In cases of non-response to nasal continuous positive airway pressure other treatments like mandibular advancement devices or upper airway surgery (especially bi-maxillary advancement) may also be considered.

Case presentation: We report the case of a 38-year-old Caucasian man with severe obstructive sleep apnoea syndrome, initially refractory to nasal continuous positive airway pressure (and subsequently also to a mandibular advancement devices), in which the visualization of the upper airway with sleep endoscopy and the concomitant titration of positive pressure were useful in the investigation and resolution of sleep disordered breathing. In fact, there was a marked reduction in the size of his nasopharynx, and a paresis of his left aryepiglottic fold with hypertrophy of the right aryepiglottic fold. The application of bi-level positive airway pressure and an oral interface successfully managed his obstructive sleep apnoea.

Conclusion: This is a rare case of obstructive sleep apnoea syndrome refractory to treatment with nocturnal ventilatory support. Visualization of the endoscopic changes, during sleep and under positive pressure, was of great value to understanding the mechanisms of refractoriness. It also oriented the therapeutic option. Refractoriness to obstructive sleep apnoea therapy with continuous positive airway pressure is rare, and each case should be approached individually.

Introduction

Obstructive sleep apnoea syndrome (OSAS) is characterized by a recurrent collapse of all or some parts of the upper airway during sleep. Despite being sub-diagnosed, it affects 2% to

4% of the world's population [1] and has a higher prevalence in obese people [2]. This syndrome is associated with increased cardiovascular risk. It is also an independent risk factor for hypertension, myocardial infarction and stroke [3].

The method for its initial evaluation using a cardiorespiratory study is simple and easy to use on an outpatient basis.

Nasal continuous positive airway pressure (nCPAP) during sleep, which allows airway patency, is the current standard treatment [4]. It significantly improves patients' excessive daytime sleepiness, states of wakefulness, cognitive abilities [5], and quality of life [6]. This treatment also decreases cardiovascular risk, especially when it is used for more than 4 hours daily [7].

Alternative treatments include a mandibular advancement device (MAD) that increases the lumen of the airway by inducing jaw and tongue protrusion during sleep, improves the tone of the muscles of the airway, and reduces the passive compliance of the pharyngeal wall [8]. It is especially effective in non-obese patients with moderate OSAS.

Upper airway surgery, specifically bi-maxillary surgery, is also effective in severe cases of OSAS. It may be considered for patients who are unwilling to use, or are refractory to, nCPAP therapy and whose anatomical changes are prone to surgical resolution [9]. This approach must be made and addressed specifically.

Case presentation

We report a 38-year-old Caucasian man who was referred to our department for suspected OSAS with complaints of severe snoring, respiratory pauses that were witnessed by his wife, morning headaches, and adynamia, but without acknowledgement of excessive daytime sleepiness.

He had a history of dyslipidemia treated with diet and statin, without the existence of other cardiovascular risk factors. He had low alcohol consumption (10 gr/day) and no history of smoking. A physical exam revealed macroglossia, a bulky soft palate and uvula. He was overweight with a body mass index (BMI) of 29.1 and had a cervical perimeter of 42 cm. As an initial diagnostic approach, a spirometry and chest X-ray were performed, which revealed no changes. A diagnostic cardiorespiratory study showed that in addition to extended periods of snoring, he also had severe OSAS with an apnoea and hypopnoea index (AHI) of 72.1/h, a desaturation index of 67.1/h, and a minimum O₂ saturation of 69%.

With the diagnosis of severe OSAS, despite the lack of excessive daytime sleepiness, a trial of positive airway pressure (automatic mode) was proposed, with the minimal pressure of 4 cmH₂O and maximum pressure of 15 cmH₂O. General measures of sleep hygiene and weight reduction were also recommended. As an

alternative, the use of MAD was considered, and the patient was referred to our hospital's orthodontics department.

The patient was evaluated after 3 months and there was no adherence to treatment, with only 3 minutes of use per night, with a total number of 6 days of use. The patient attributed this to his difficulty in adapting to the masks and to the pressure itself.

MAD (Figure 1) was applied over the next 3 months. During this period, our patient used the device daily for 3 to 4 hours per night, as limited by some salivation and gum pain. His clinical symptoms, however, did not improve.

For a better evaluation of our patient's clinical response, we did a home cardiorespiratory study using MAD (Figure 2), which showed no significant improvement in his OSAS. (He had an AHI of 61.4/h and desaturation index of 42.1/h with MAD during the first 3.5 hours of recording).

To titrate CPAP pressures and to better characterize our patient's sleep structure, we conducted a split-night polysomnography. The first part of the night confirmed the severity of our patient's OSA (AHI of 64.9/h with minimum O₂ saturation of 29%). The second part allowed a gradual increase of positive pressure, first in continuous mode (CPAP) for up to 16 cmH₂O, then in the bilevel mode (BiPAP) with a maximum inspiratory pressure (IPAP) of 24 cmH₂O and a maximum expiratory pressure (EPAP) of 20 cmH₂O. Persistent obstructive events with marked desaturation, with a minimum O₂ saturation of 45% in CPAP mode and of 82% in BiPAP mode (Figure 3) were prevalent.



Figure 1
An example of a mandibular advancement device.




Figure 2

A cardiorespiratory study in the use of a mandibular advancement device. An evaluation at 4 months with a cardiorespiratory study in the use of a mandibular advancement device (first 3.5 h of study) showed no significant improvement in the patient's obstructive sleep apnoea syndrome (apnoea and hypopnoea index at 61.4/h and desaturation index of 42.1/h). A severe condition of obstructive sleep apnoea syndrome was observed with and without the use of the device.

Since the nocturnal titration was ineffective, a retitration of pressures was conducted during the day to confirm this refractoriness and optimize the interface. At that moment the patient was prescribed bilevel-positive air pressure (VIVO 30, Breas) with 20 cmH₂O of IPAP and 12 cmH₂O of EPAP and a gel face mask (Mojo).

After a period with these settings, the patient's symptoms remained, but he developed a newly diagnosed hypertension, which was treated with antihypertensive medication. Home nocturnal oximetry (in bilevel mode with those parameters) maintained episodes of desaturation, suggesting a large number of residual apnoea and/or hypopnoea events (Figure 4).

His refractoriness led to further investigations which were done using two methods of evaluation. In the first one, a facial computed tomography (CT) revealed a smaller upper airway (Figure 5). Reformatting (Figure 6) showed an angular dysmorphism at the hypopharynx [10].


The second method used sleep nasoendoscopy (Figure 7) with concomitant polysomnography and titration of ventilatory support pressures (Figure 8) [6]. In this

evaluation, the patient was able to sleep effectively, and a marked reduction of the size of the nasopharynx and a paresis of the left aryepiglottic fold with hypertrophy of the right one (Figure 7A) were noted. Extended periods of vibration of the walls of the oropharynx related to snores were also observed. With the establishment of positive pressure ventilation, a subocclusion of the nasopharynx persisted (up to IPAP/EPAP levels of 24/16 cmH₂O). An unrolling of the epiglottis that collapsed the airway and provoked periods of O₂ desaturation (Figure 7C) was noted a few times. These episodes improved under 20 cmH₂O IPAP and 13 cmH₂O EPAP with an Oracle® mask. A home oximetry under a bilevel mode with these pressures and interface (Figure 9) revealed a significant improvement in our patient's nocturnal desaturation episodes.


Discussion

Refractoriness of OSAS therapy is rare and its approach should be targeted to specific individuals.

The conventional method for administering CPAP is using a nasal or oronasal interface [11] based on

**Figure 3**

Split-night polysomnography: Obstructive sleep apnoea syndrome refractoriness with continuous positive airway pressure and bilevel positive airway pressure, nasal mask. (Evaluation at 4 months). The first part of the night confirmed the severity of obstructive sleep apnoea syndrome (apnoea and hypopnoea index of 64.9/h with minimum O₂ saturation of 29%). The second part allowed a gradual increase in positive pressure, first in continuous positive airway pressure for up to 16 cmH₂O, then in bilevel positive airway pressure with a maximum inspiratory pressure of 24 cmH₂O and a maximum expiratory pressure of 20 cmH₂O. There were persistent obstructive events with marked desaturation (minimum O₂ saturation of 45% in continuous mode and of 82% in bilevel mode).

**Figure 4**

A home nocturnal oximetry (in bilevel mode) with nasal mask. (Evaluation at 5 months). A home nocturnal oximetry (in bilevel mode, inspiratory pressure of 20 cmH₂O and expiratory pressure of 12 cmH₂O, and a gel face mask (Mojo) shows episodes of desaturation suggesting a large number of residual apnoea and/or hypopnoea events.




Figure 5
A facial computed tomography at 5.5 months following the initial presentation shows a smaller upper airway.




Figure 6
A facial computed tomography reformation at 5.5 months after the initial presentation shows an angular dysmorphism at the hypopharynx level.





Figure 7
(A) Sleep endoscopy before ventilation. Extended periods of vibration of the walls of the oropharynx related to snores were observed. With the establishment of positive pressure ventilation, the nasopharynx subocclusion persisted up to 24 cmH₂O inspiratory pressure and 16 cmH₂O expiratory pressure. An unrolling of the epiglottis that collapsed the airway and provoked periods of O₂ desaturation was also noted. **(C)** Sleep nasoendoscopy under continuous positive airway pressure with P > 16 cmH₂O at 6 months after the initial presentation. In this evaluation, a marked reduction of the size of the nasopharynx, and a paresis of the left aryepiglottic fold with hypertrophy of the right one were noted.

increasing intramural pressure above a critical point of oropharynx collapse (PCrit) [12]. Patients' compliance to treatment is somewhat constrained by the side effects associated with the use of these interfaces, such as nasal congestion, dryness of the oronasal mucosa, epistaxis, and claustrophobia. The oral route is an alternative that can be used in cases where the patient is intolerant to conventional approaches [13].


According to recent literature [14], the air acts as a resistor to the physiological nasal obstruction which produces collapsing forces that manifest at the most collapsible point, the pharynx. Positive pressure applied through the nose has to overcome the PCrit that results from the composition of pressure at the point of collapse of the airway and the surrounding soft tissue. Because the soft palate is complacent, the PCrit to be overcome is similar to the positive pressure that is applied through the mouth. The Oracle mask (Fisher and Paykel) has shown to be effective in the treatment of OSAS [13], as it applies a pressure-flow relationship to the oropharynx



7 11 1

1 0 1

9 1 1



of great value to the understanding of the mechanisms of refractoriness.

The application of a positive pressure in an airway with anatomical changes (such as occurred in the case described) could perhaps have caused valve mechanisms

that led to the unrolling of the epiglottis, with consequent obstruction to the passage of air. This phenomenon has become more evident with pressure levels greater than 16 cmH₂O. At the same time, with lower pressures, the patency of the airway was not established.

Based on these findings, the clinical decision to administer bilevel positive pressure during sleep through an oral mask, which is not usually used in patients with OSAS, overcame the major collapse of our patient's nasopharynx.

Conclusion

We describe a rare case of OSAS with refractoriness to treatment with nocturnal ventilatory support and emphasize the importance of endoscopic visualization of the upper airway during sleep in order to clarify the origin of refractoriness and concomitantly orient the treatment.

Consent

Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.

Competing interests

The authors declare that they have no competing interests.

Authors' contributions

CL analyzed and interpreted the patient data regarding OSAS and reviewed the existing literature on this issue. MD also analyzed and interpreted the patient data and was a major contributor in writing the manuscript. AM performed the sleep nasoendoscopy. MG performed the adaptation to noninvasive ventilation. ESC analyzed the polyssonographic data. JW orientated the investigation and therapeutic options and was a major contributor in writing the manuscript. All authors read and approved the final manuscript.

References

- Young T, Palta M, Dempsey J, Skatrud J, Weber S and Badr S: **The occurrence of sleep-disordered breathing among middle-aged adults.** *N Engl J Med* 1993, **328**:1230–1235.
- Van Boxem TJM and de Groot GH: **Prevalence and severity of sleep-disordered breathing in a group of morbidly obese patients.** *Neth J Med* 1999, **54**(5):202–206.
- Nieto FJ, Young TB, Lind BK, Shahar E, Samet JM, Redline S, Dągostino RB, Newman AB, Lebowitz MD and Pickering TG: **Association of sleep-disordered breathing, sleep Apnoea, and hypertension in a large community-based study: sleep heart health study.** *JAMA* 2000, **283**(14):1829–1836.
- Parish JM and Somers VK: **Obstructive sleep apnoea and cardiovascular disease.** *Mayo Clin Proc* 2004, **79**(8):1036–1046.
- Chisholm E and Kotecha B: **Oropharyngeal surgery for obstructive sleep apnoea in CPAP failures.** *Eur Arch Otorhinolaryngol* 2007, **264**:51–55.
- Baish A, Hein G, Gobler J, Maurer T and Hormann K: **Finding the appropriate therapy with the help of sleep endoscopy.** *Laryngo-Rhino-Otol* 2005, **84**:833–837.
- Lojander J, Räsänen P, Sintonen H, Roine RP and HUS QoL Study Group: **Effect of nasal continuous positive airway pressure therapy on health related quality of life in sleep apnoea patients treated in the routine clinical setting of a university hospital.** *J Int Med Res* 2008, **36**(4):760–770.
- Santamaria J, Iranzo A, Ma Montserrat J and de Pablo J: **Persistent sleepiness in CPAP treated obstructive sleep apnoea patients: evaluation and treatment.** *Sleep Med Rev* 2007, **11**(3):195–207.
- Baptista PM: **Surgery for obstructive sleep apnoea.** *An Sist Sanit Navar* 2007, **30**(Suppl 1):75–88.
- Maurer JT, Stuck BA, Hein G and Hormann K: **Videoendoscopic assessment of uncommon sites of upper airway obstruction during sleep.** *Sleep Breath* 2000, **4**(3):131–136.
- Petri N, Svanholt P, Solow B and Winkel P: **Mandibular advancement appliance for obstructive sleep apnoea: results of randomised placebo controlled trial using parallel group design.** *J Sleep Res* 2008, **17**(2):221–229.
- Rama NA, Tekwani SH and Kushida CA: **Sites of obstruction in obstructive sleep apnoea.** *Chest* 2002, **122**:1139–1147.
- Smith LP, O'Donnell CP, Allan L and Schwartz AR: **A physiologic comparison of nasal and oral positive airway pressure.** *Chest* 2003, **123**:689–694.
- McNicholas WT: **The nose and OSA: variable nasal obstruction may be more important in pathophysiology than fixed obstruction.** *Eur Respir J* 2008, **32**:3–8.
- Khanna R and Kline LR: **A prospective eight-week trial of nasal interfaces versus a novel oral interface (Oracle) for treatment of obstructive sleep apnoea hypopnoea syndrome.** *Sleep Med* 2003, **4**(4):333–338.

Publish with **BioMed Central** and every scientist can read your work free of charge

"BioMed Central will be the most significant development for disseminating the results of biomedical research in our lifetime."

Sir Paul Nurse, Cancer Research UK

Your research papers will be:

- available free of charge to the entire biomedical community
- peer reviewed and published immediately upon acceptance
- cited in PubMed and archived on PubMed Central
- yours — you keep the copyright

Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp

